Dr. Catenacci on Study of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer
March 1st 2018Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.
Read More
Dr. Catenacci on Results of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer
January 20th 2018Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, Univeristy of Chicago Medicine, discusses margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) as treatment for patients with advanced HER2-positive gastroesophageal junction (GEJ) or gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.
Read More